Balyasny Asset Management
AMRX icon

Balyasny Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Balyasny Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.51M Buy
434,132
+355,009
+449% +$4.86M 0.01% 1196
2026
Q1 		$983K Sell
79,123
-610,744
-89% -$8.2M ﹤0.01% 2088
2025
Q4 		$8.69M Buy
689,867
+43,681
+7% +$500K 0.01% 1098
2025
Q3 		$6.47M Buy
646,186
+446,197
+223% +$4M 0.01% 1258
2025
Q2 		$1.62M Sell
199,989
-519,091
-72% -$3.91M ﹤0.01% 1841
2025
Q1 		$6.03M Buy
719,080
+546,767
+317% +$4.56M 0.01% 1158
2024
Q4 		$1.36M Buy
+172,313
New +$1.45M ﹤0.01% 1822
2023
Q4 		– Sell
-29,594
Closed -$125K – 2466
2023
Q3 		$125K Buy
+29,594
New +$110K ﹤0.01% 2099
2020
Q2 		– Sell
-24,151
Closed -$84K – 1106
2020
Q1 		$84K Buy
+24,151
New +$102K ﹤0.01% 1086
2019
Q3 		– Sell
-32,834
Closed -$235K – 1141
2019
Q2 		$235K Sell
32,834
-95,287
-74% -$974K ﹤0.01% 1377
2019
Q1 		$1.81M Buy
128,121
+60,605
+90% +$801K 0.01% 851
2018
Q4 		$913K Sell
67,516
-4,958
-7% -$89.3K 0.01% 928
2018
Q3 		$1.61M Buy
+72,474
New +$1.53M 0.01% 1051

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Balyasny Asset Management's AMRX Position: Q2 2026 in Review

Balyasny Asset Management increased its Amneal Pharmaceuticals (AMRX) stake by 449% in Q2 2026, buying an estimated $4.86M and bringing the position to 434,132 shares worth $7.51M. The position accounts for 0.01% of the portfolio, ranked #1196.

Balyasny Asset Management first reported a position in AMRX in Q3 2018 and has held it in 13 quarters since. The position peaked at $8.69M in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Balyasny Asset Management held 434,132 shares of Amneal Pharmaceuticals worth $7.51M as of Q2 2026.
  • Balyasny Asset Management bought 355,009 Amneal Pharmaceuticals shares in Q2 2026, an estimated $4.86M.
  • Amneal Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1196 holding.
  • Balyasny Asset Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and has held it in 13 quarters since.
  • Balyasny Asset Management's Amneal Pharmaceuticals position peaked at $8.69M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.